20170406 Telix Logo.png
Telix Enters Commercial Distribution Agreement for Illuccix® in Australia
15 févr. 2022 17h39 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into a commercial distribution agreement with...
20170406 Telix Logo.png
Japanese Prostate Cancer Imaging Trial Meets Study Objectives
07 févr. 2022 18h08 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
20170406 Telix Logo.png
Telix and Biokosmos Sign Distribution Agreement for Prostate Cancer Imaging in Greece and Cyprus
27 janv. 2022 16h41 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and ATHENS, Greece, Jan. 28, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
FDA Approves Telix’s Prostate Cancer Imaging Product, Illuccix®
19 déc. 2021 16h47 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company), a global biopharmaceutical company focused on the development...
20170406 Telix Logo.png
Telix and NUCLIBER Sign Distribution Agreement for Prostate Cancer Imaging in Spain
07 déc. 2021 17h42 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and MADRID, Spain, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has entered into an exclusive...
20170406 Telix Logo.png
Illuccix® Granted Use Authorisation for Prostate Cancer Imaging in Brazil
30 nov. 2021 16h45 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and PORTO ALEGRE, Brazil, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Brazilian Health Regulatory...
20170406 Telix Logo.png
Australian TGA Approves Illuccix® for Prostate Cancer Imaging
01 nov. 2021 19h25 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Australian Therapeutic Goods Administration (TGA) has...
20170406 Telix Logo.png
Two New Studies to Explore Telix Assets in Breast Cancer Theranostics
17 août 2021 21h26 HE | Telix Pharmaceuticals Limited
Breast cancer one of several important indication expansion opportunities for the Telix portfolioFirst patient dosed at Emory University (Atlanta, USA) in a Phase I study of TLX591-CDx for the staging...
20170406 Telix Logo.png
Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®
30 mars 2021 18h02 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and INDIANAPOLIS, March 30, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that it has completed an agreement with...
20170406 Telix Logo.png
Czech Republic First European Country to Grant National Authorisation for the Use of Telix’s Prostate Cancer Imaging Product
16 févr. 2021 01h05 HE | Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) announces today that the Ministry of Health of the...